Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2024 | BTK inhibitors for MS treatment: what do the recent trial readouts mean for the field?

Giancarlo Comi, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses the recent readouts of two Phase III trials, which compared the experimental BTK inhibitor (BTKi) evobrutinib to the disease-modifying drug teriflunomide in patients with multiple sclerosis (MS). The results of these studies were negative, causing disappointment within the community. However, although the BTKi was not found to be superior to teriflunomide in reducing acute inflammation, its effect was comparable. Therefore, Prof. Comi highlights the need to remain open to the potential of the BTKi drug class to have an effect on the mechanisms of neurodegeneration in MS and not simply rule it out as a treatment option due to the lack of a superior anti-inflammatory effect. This interview took place at the 18th Annual Congress on Controversies in Neurology (CONy 2024) in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.